Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2013

01-01-2013 | Original Article

T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile

Authors: Shahryar Kiaii, Parviz Kokhaei, Fariba Mozaffari, Eva Rossmann, Fatemeh Pak, Ali Moshfegh, Marzia Palma, Lotta Hansson, Kaveh Mashayekhi, Mohammad Hojjat-Farsangi, Anders Österborg, Aniruddha Choudhury, Håkan Mellstedt

Published in: Cancer Immunology, Immunotherapy | Issue 1/2013

Login to get access

Abstract

T cells may have a role in sustaining the leukemic clone in chronic lymphocytic leukemia (CLL). In this study, we have examined the ability of T cells from CLL patients to support the survival of the leukemic B cells in vitro. Additionally, we compared global gene expression of T cells from indolent CLL patients with healthy individuals and multiple myeloma (MM) patients. Apoptosis of purified leukemic B cells was inhibited in vitro when co-cultured with increasing numbers of autologous T cells (p < 0.01) but not autologous B and T cells of normal donors. The anti-apoptotic effect exceeded that of the anti-apoptotic cytokine IL-4 (p = 0.002) and was greater with CD8+ cells (p = 0.02) than with CD4+ cells (p = 0.05). The effect was depended mainly on cell–cell contact although a significant effect was also observed in transwell experiments (p = 0.05). About 356 genes involved in different cellular pathways were deregulated in T cells of CLL patients compared to healthy individuals and MM patients. The results of gene expression profiling were verified for 6 genes (CCL4, CCL5 (RANTES), XCL1, XCL2, KLF6, and TRAF1) using qRT–PCR and immunoblotting. Our results demonstrate that CLL-derived T cells can prevent apoptosis of leukemic B cells and have altered expression of genes that may facilitate the survival of the leukemic clone.
Appendix
Available only for authorised users
Literature
1.
Bo MD, Bomben R, Zucchetto A et al (2012) Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. Curr Pharm Des. pii:CPD-EPUB-20120510-1
2.
Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804–815PubMedCrossRef
3.
Ghia P, Caligaris-Cappio F (2006) The origin of B-cell chronic lymphocytic leukemia. Semin Oncol 33(2):150–156PubMedCrossRef
4.
Kiaii S, Choudhury A, Mozaffari F et al (2005) Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease. Med Oncol 22(3):291–302PubMedCrossRef
5.
Mellstedt H, Choudhury A (2006) T and B cells in B-chronic lymphocytic leukaemia: faust, mephistopheles and the pact with the devil. Cancer Immunol Immunother 55(2):210–220PubMedCrossRef
6.
Mellstedt H, Pettersson D (1974) Lymphocyte subpopulations in chronic lymphocytic leukemia. Characterization by cell surface markers, cytotoxic activity, and mitogenic stimulation. Scand J Immunol 3(3):303–310PubMedCrossRef
7.
Scrivener S, Goddard RV, Kaminski ER et al (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 44(3):383–389PubMedCrossRef
8.
Kiaii S, Choudhury A, Mozaffari F et al (2006) Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leuk Lymphoma 47(7):1229–1238. doi:10.​1080/​1042819060056550​3 PubMedCrossRef
9.
Palma M, Kokhaei P, Lundin J et al (2006) The biology and treatment of chronic lymphocytic leukemia. Ann Oncol 17(Suppl 10):x144–x154PubMedCrossRef
10.
Rossmann ED, Lewin N, Jeddi-Tehrani M et al (2002) Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol 68(5):299–306PubMedCrossRef
11.
Ghia P, Caligaris-Cappio F (2000) The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 79:157–173PubMedCrossRef
12.
Ghia P, Circosta P, Scielzo C et al (2005) Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 294:135–145PubMedCrossRef
13.
Ghia P, Strola G, Granziero L et al (2002) Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 32(5):1403–1413PubMedCrossRef
14.
Granziero L, Circosta P, Scielzo C et al (2003) CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood 101(5):1962–1969PubMedCrossRef
15.
Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87(12):4990–4997PubMed
16.
Boyum A (1977) Separation of lymphocytes, lymphocyte subgroups and monocytes: a review. Lymphology 10(2):71–76PubMed
17.
Ni H, Ergin M, Tibudan SS et al (2003) Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis. Br J Haematol 121(6):849–856PubMedCrossRef
18.
19.
20.
21.
Gorgun G, Holderried TA, Zahrieh D et al (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115(7):1797–1805PubMedCrossRef
22.
Nishio M, Endo T, Tsukada N et al (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 106(3):1012–1020PubMedCrossRef
23.
Kurtova AV, Balakrishnan K, Chen R et al (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114(20):4441–4450. doi:10.​1182/​blood-2009-07-233718 PubMedCrossRef
24.
Mohle R, Failenschmid C, Bautz F et al (1999) Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 13(12):1954–1959PubMedCrossRef
25.
Pedersen IM, Kitada S, Leoni LM et al (2002) Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100(5):1795–1801PubMed
26.
Tinhofer I, Weiss L, Gassner F et al (2009) Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother 32(3):302–309. doi:10.​1097/​CJI.​0b013e318197b5e4​ PubMedCrossRef
27.
Gamberale R, Geffner J, Arrosagaray G et al (2001) Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis. Leukemia 15(12):1860–1867PubMedCrossRef
28.
Lundin J, Kimby E, Bergmann L et al (2001) Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. Br J Haematol 112(1):155–160. pii:bjh2525
29.
30.
Coscia M, Pantaleoni F, Riganti C et al (2011) IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 25(5):828–837. doi:10.​1038/​leu.​2011.​12 PubMedCrossRef
31.
32.
Colombara M, Antonini V, Riviera AP et al (2005) Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. J Immunol 175(10):7021–7028. pii:175/10/7021
33.
Ek S, Bjorck E, Hogerkorp CM et al (2006) Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4–1BB-L implicated in cell survival. Int J Cancer 118(8):2092–2097. doi:10.​1002/​ijc.​21579 PubMedCrossRef
34.
Walunas TL, Lenschow DJ, Bakker CY et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5):405–413PubMedCrossRef
35.
36.
Billard C, Kern C, Tang R et al (2003) Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 17(12):2435–2443PubMedCrossRef
37.
Levesque MC, Misukonis MA, O’Loughlin CW et al (2003) IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. Leukemia 17(2):442–450PubMedCrossRef
38.
Zhao H, Dugas N, Mathiot C et al (1998) B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92(3):1031–1043PubMed
39.
Nabeshima S, Nomoto M, Matsuzaki G et al (1999) T-cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice infected with Mycobacterium tuberculosis. Infect Immun 67(7):3221–3226PubMed
40.
van der Veen RC (2001) Nitric oxide and T helper cell immunity. Int Immunopharmacol 1(8):1491–1500PubMedCrossRef
41.
Zapata JM, Krajewska M, Morse HC III et al (2004) TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 101(47):16600–16605. doi:10.​1073/​pnas.​0407541101 PubMedCrossRef
42.
43.
44.
45.
Razzaq TM, Ozegbe P, Jury EC et al (2004) Regulation of T-cell receptor signalling by membrane microdomains. Immunology 113(4):413–426PubMedCrossRef
46.
Bromley SK, Burack WR, Johnson KG et al (2001) The immunological synapse. Annu Rev Immunol 19:375–396. pii:19/1/375
47.
Stinchcombe JC, Bossi G, Booth S et al (2001) The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15(5):751–761PubMedCrossRef
48.
Waugh SM, Harris JL, Fletterick R et al (2000) The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity. Nat Struct Biol 7(9):762–765. doi:10.​1038/​78992 PubMedCrossRef
Metadata
Title
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Authors
Shahryar Kiaii
Parviz Kokhaei
Fariba Mozaffari
Eva Rossmann
Fatemeh Pak
Ali Moshfegh
Marzia Palma
Lotta Hansson
Kaveh Mashayekhi
Mohammad Hojjat-Farsangi
Anders Österborg
Aniruddha Choudhury
Håkan Mellstedt
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1300-y

Other articles of this Issue 1/2013

Cancer Immunology, Immunotherapy 1/2013 Go to the issue

Original Article

T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer

Meeting report

“Tumor Immunology Meets Oncology (TIMO) VIII” from May 4 to 5, 2012, in Halle/Saale, Germany

Original article

A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response

Original article

Increased prevalence of tumor-infiltrating regulatory T cells is closely related to their lower sensitivity to H2O2-induced apoptosis in gastric and esophageal cancer

Original article

CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients

Original article

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits